Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
DC CAFCFirst Claim
Patent Images
1. An isolated monoclonal antibody that binds to PCSK9, wherein the isolated monoclonal antibody binds an epitope on PCSK9 comprising at least one of residues 237 or 238 of SEQ ID NO:
- 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
135 Citations
24 Claims
-
1. An isolated monoclonal antibody that binds to PCSK9, wherein the isolated monoclonal antibody binds an epitope on PCSK9 comprising at least one of residues 237 or 238 of SEQ ID NO:
- 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
13. An isolated monoclonal antibody that binds to human PCSK9 at one or more of amino acid residues 237 or 238 of SEQ ID NO:
- 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
- View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
Specification